Sourcing guide · research use only
Where to buy cagrilintide for research.
Cagrilintide is a long-acting amylin analog studied in laboratory research — an amylin-receptor agonist, not a GLP-1 compound, even though it is frequently co-studied alongside semaglutide. Its folded, cyclic, acylated structure changes what a real certificate of analysis has to prove. This guide covers what to verify before buying cagrilintide, why an amylin analog needs more than a linear-sequence COA, and the documented next-generation metabolic-research peptide Titan actually stocks. It makes no human-use, dosing, or efficacy claims.
Before you buy
What an amylin-analog COA must prove.
A cagrilintide document has to do everything a short-peptide COA does — and then prove the molecule is folded, cyclized, amidated, and acylated correctly. Run any cagrilintide listing against this table before you trust the purity number on it.
| What to check | What a real COA shows | Red flag |
|---|---|---|
| Sequence identity (MS) | Mass spectrometry confirming the full amylin-analog sequence — including the acylation (lipid) modification that gives cagrilintide its long-acting profile, not just the bare peptide backbone | A purity number with no mass-spec identity, or a mass that ignores the acyl chain entirely |
| Disulfide bridge formed | Confirmation the intramolecular disulfide bond is correctly closed — amylin and its analogs are cyclic, and a reduced (open) chain is a different molecule with the same residue count | No mention of the disulfide / cyclization at all — a sequence-only COA can't prove the ring is intact |
| C-terminal amidation | Verification the C-terminus is amidated as the analog requires — a free-acid C-terminus is a synthesis failure that mass-spec can distinguish | Silent on terminal chemistry; the COA treats it like a generic linear peptide |
| Purity figure (HPLC) | Purity stated against the correctly folded, acylated analog with an HPLC chromatogram shown and the method named — not a marketing round number | "99%+" with no chromatogram, no method, and no reference to the fold or acyl group |
| Lot / batch + compliance | A lot code matching the vial, documentation silent on human use | A generic reused COA, mismatched lot, or human-use / dosing / weight claims |
Cagrilintide is an amylin analog, not a GLP-1
This is the point most listings get wrong. Cagrilintide is a long-acting analog of amylin — it is studied as an amylin-receptor agonist, a different receptor system from the GLP-1, GIP, and glucagon incretin pathways. It is frequently co-studied alongside semaglutide in laboratory research (the combination researchers call CagriSema), which is why buyers conflate it with GLP-1 compounds. Mechanistically it belongs to a separate class, and that matters when you read its certificate of analysis.
Incretin research classes →Why a cagrilintide COA needs more than a sequence
An amylin analog is a folded, cyclic, modified molecule. A real cagrilintide certificate of analysis has to confirm three things a linear-peptide COA skips: that the intramolecular disulfide bond is correctly formed (a reduced chain is a different molecule), that the C-terminus is amidated, and that the acylation — the fatty-acid modification that makes cagrilintide long-acting — is present and accounted for in the measured mass. A bare purity percentage proves none of this.
How to read a COA →What Titan stocks in the metabolic-research space
Titan does not currently list cagrilintide. Rather than sell a compound it does not test in-house, this guide points researchers to the verification standard that applies to any amylin-analog source and to the in-catalog next-generation metabolic-research option Titan documents: retatrutide, a triple GLP-1 / GIP / glucagon receptor agonist, lot-matched to a COA. It is a different mechanism than cagrilintide — an incretin-class agonist rather than an amylin analog — but it is the documented next-gen option Titan can stand behind.
Retatrutide for sale →Red flags on cagrilintide listings
Walk away from any cagrilintide source whose documentation carries dosing, weight, appetite, or other human-use claims — that is a compliance red flag, not a quality spec. Be skeptical of a COA that states a purity number with no chromatogram, says nothing about the disulfide bond or C-terminal amidation, reports a mass that ignores the acyl chain, reuses one generic document across products, or carries a lot code that doesn't match the vial.
Sourcing research compounds →How Titan fulfills metabolic-research orders
Documented, lot-matched, crypto checkout.
- 1. Verify the document before the molecule. For any amylin or incretin-class compound, confirm the COA shows a chromatogram, names the HPLC method, confirms identity by mass spectrometry, and accounts for the fold and any acyl modification — a folded peptide is more than its residue list.
- 2. Lot-matched documentation. Titan’s in-catalog next-gen metabolic option, retatrutide, ships referenced to a batch code with an HPLC purity target and identity confirmation.
- 3. Crypto-only checkout. USDC, BTC, and SOL accepted; stablecoin keeps the total fixed from cart to on-chain confirmation.
- 4. Verify it yourself. Match the lot code to the vial and read the chromatogram — don’t accept a purity number on a folded, acylated analog without one.
Cagrilintide is a long-acting amylin analog studied in laboratory research as an amylin-receptor agonist, distinct from the GLP-1 incretin class it is often paired with. Titan does not currently list it; its documented next-generation metabolic-research option is retatrutide, a triple GLP-1 / GIP / glucagon agonist. Everything here is supplied strictly for research use only, with no human-use, dosing, or efficacy claims. This page is about sourcing and verification, not use.
Related reading